MITF and renal carcinoma: Compared to non-carriers, MITF-E318K carriers have a higher risk of developing CM in association with other tumors, including pancreatic and renal cancer [11,21], while there is minimal evidence of MITF-E318K contribution to non-melanoma cancer risk [22].